A Closer Look At The Efficacy Of Bioengineered Alternative Tissues For DFUs

Melissa Skratsky, DPM, and Stephanie Wu, DPM, MSc

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(10):1047-53.
2. Singh H, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293(2):217-28.
3. Smith D, Weinberger M, Katz B. A controlled trial to increase office visits and reduce hospitalization in diabetic patients. J Gen Intern Med. 1987; 2(4):232-8.
4. Ollendorf D, Kotsanos J, Wishner W. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care. 1998; 21(8):1240-1245.
5. Lavery LA, van Houtum WH, Armstrong DG, Harkless LB, Ashry HR, Walker SC. Mortality following lower extremity amputation in minorities with diabetes mellitus. Diabetes Res Clin Pract. 1997; 37(1):41-7.
6. Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003; 26(6):1879-82.
7. Eisenbud D, Ngan F, Luke S, Silberklang M. Skin substitutes and wound healing: current status and challenges. Wounds. 2004; 16(1):2-17.
8. Phillips TJ, Manzoor J, Rojas A, et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002; 138(8):1079-81.
9. Krejci-Papa NC, Hoang A, Hansbrough JF. Fibroblast sheets enable epithelialization of wounds that do not support keratinocyte migration. Tissue Eng. 1999; 5(6):555-62.
10. Michel M, L’Heureux NL, Auger FA, Germain L. From newborn to adult: Phenotypic and functional properties of skin equivalent and human skin as a function of donor age. J Cell Physiol. 1997; 171(2):179-81.
11. Van der Veen V, van der Wal M, van Leeuwen M, Ulrich M, Middelkoop E. Biological background of dermal substitutes. Burns. 2010; 36(3):305-21.
12. Kim P, Heilala M, Steinberg J, Weinraub G. Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing. Clin Podiatr Med Surg. 2007; 24(3):529-46.
13. Hodde J, Ernst D, Hiles M. An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. J Wound Care. 2005; 14(1):23-5.
14. Mostow EN, Haraway GD, Dalsing M, et al. OASIS Venous Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005; 41(5):837-43.
15. Niezgoda JA, Van Gils CC, Frykberg RG, et al. Oasis Diabetic Ulcer Study Group. Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Adv Skin Wound Care. 2005; 18(5):258-66.
16. Ralston DR, Layton C, Dalley AJ, Boyce SG, Freedlander E, Mac Neil S. The requirement for basement membrane antigen in the production of human epidermal/dermal composites in vitro. Br J Dermatol. 1999; 140(4):605-15.
17. Brigido SA. The use of acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006; 3(3):181-7.
18. Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterial, wound healing, embryonic development, stem cells and regeneration. JR Soc Interface. 2007; 4(14):413-37.
19. Redekop W, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003; 21(16):1171-83.
20. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24(2):290-5.
21. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers, results from a prospective randomized trial. Diabetes Care. 2003; 26(6):1701-5.
22. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterial for stimulated cell adhesion and beyond. Biomaterials. 2003; 24(24):4385-415.

Add new comment